CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study
British Journal of Haematology · 2025
DOI: 10.1111/bjh.19967 ↗Kurz gefasst
Klinische Studie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Chezi Ganzel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew Univ…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jazz Pharmaceuticals.
Abstract (Originalsprache)
This pilot study evaluated CPX‐351 in adults with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD‐negative AML. Twenty patients received CPX‐351 for induction, with six also receiving gemtuzumab ozogamicin (GO). The complete response rate was 95%, with 42% achieving flow‐based minimal residual disease (MRD) negativity post‐induction. The 18‐month leukaemia‐free and overall survival estimates were 80% and 95% respectively. Adding GO appeared safe without prolonged cytopenias. Subclinical cardiotoxicity was observed in 25% of patients. The study demonstrated CPX‐351's feasibility, with response and MRD‐negativity rates comparable to standard ‘7 + 3’ induction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.
- Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Hematology and Bone Marrow Transplantation Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Flow Cytometry Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel.
ORCID-Profile: Chezi Ganzel, Yishai Ofran
Förderung
- Jazz Pharmaceuticals
Zitieren
APA
Ganzel, C., Frisch, A., Wolach, O., Moshe, Y., Krayem, B., Dor, N., Broide, E., Benayoun, E., Rowe, J. M., & Ofran, Y. (2025). CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study. British Journal of Haematology. https://doi.org/10.1111/bjh.19967
Vancouver
Ganzel C, Frisch A, Wolach O, Moshe Y, Krayem B, Dor N, et al. CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study. British Journal of Haematology. 2025. doi:10.1111/bjh.19967
BibTeX
@article{Ganzel2025,
author = {Ganzel, Chezi and Frisch, Avraham and Wolach, Ofir and Moshe, Yakir and Krayem, Baher and Dor, Neta and Broide, Etti and Benayoun, Emmanuel and Rowe, Jacob M and Ofran, Yishai},
title = {CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.19967}
}
EUVIMED